The Effects of Ibuprofen and Laser on Orthodontic Pain

August 26, 2019 updated by: Yeşim KAYA

Comparison of the Effects of Ibuprofen and Low-Level Laser Therapy on Orthodontic Pain By Means of Interleukin 1-Beta and Substance P Levels in the Gingival Crevicular Fluid

Early orthodontic pain is usually caused by the insertion of elastomeric separators to the mesial and distal of the tooth to be banded in order to create adequate space for proper placement. Recent studies have demonstrated that the pain reaches its peak at 24 hours and then gradually decreases within 7 days The intensity of this pain is sometimes perceived as extremely high to cause a significant number of patients to discontinue the treatment.

Nonsteroidal anti-inflammatory drugs, which block the prostaglandin synthesis through inhibiting the cyclooxygenase activity, is one of the most common methods used to manage the orthodontic pain. It has been reported that these drugs decrease the orthodontic tooth movement rate, in addition to many systemic side effects such as gastric and duodenal ulceration, coagulation disorders, congestive heart problems and allergic effect.

The application of low-level laser therapy (LLLT) also reported being efficient in accelerating orthodontic tooth movement and in alleviating orthodontic pain without any apparent side effects. LLLT is thought to reduce the pain by increasing the local blood flow, inhibiting the secretion of inflammatory substances, inducing the release of neurotransmitters, altering the conduction and excitation of peripheral nerves and stimulating the endorphins release. On the other hand, literature review on the effectiveness of LLLT in alleviating orthodontic pain observed after elastomeric separator placement (ESP) exhibited conflicting results. While LLLT was found to be effective in some studies, the others refuted its effectiveness.

When studies on alleviating orthodontic pain observed after ESP were reviewed, it was determined that the effects of many drugs and LLLT were evaluated subjectively by VAS. Furthermore, only in one study, the effects of ibuprofen and LLLT were compared using PGE2 levels in GCF and VAS. Based on that, this study was aimed to compare the effects of ibuprofen and LLLT in alleviating orthodontic pain observed after ESP through IL-1β and SP levels in GCF and VAS.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Pain is defined as a sophisticated experience that includes sensations evoked by, and reactions to noxious stimuli. During the different phase of orthodontic treatment, pain is developed in response to the tension and pressure zones generated in the periodontal ligament following the force application. This leads to the secretion of inflammatory mediators such as histamine, serotonin, dopamine, glycine, cytokines, leukotrienes, prostaglandins and substance P that stimulate free nerve endings resulting in the perception of pain.

Early orthodontic pain is usually caused by the insertion of elastomeric separators to the mesial and distal of the tooth to be banded in order to create adequate space for proper placement. Recent studies have demonstrated that the pain reaches its peak at 24 hours and then gradually decreases within 7 days. The intensity of this pain is sometimes perceived as extremely high to cause a significant number of patients to discontinue the treatment.

Nonsteroidal anti-inflammatory drugs, which block the prostaglandin synthesis through inhibiting the cyclooxygenase activity, is one of the most common methods used to manage the orthodontic pain. It has been reported that these drugs decrease the orthodontic tooth movement rate, in addition to many systemic side effects such as gastric and duodenal ulceration, coagulation disorders, congestive heart problems and allergic effect.

The application of low-level laser therapy (LLLT) also reported being efficient in accelerating orthodontic tooth movement and in alleviating orthodontic pain without any apparent side effects. LLLT is thought to reduce the pain by increasing the local blood flow, inhibiting the secretion of inflammatory substances, inducing the release of neurotransmitters, altering the conduction and excitation of peripheral nerves and stimulating the endorphins release. On the other hand, literature review on the effectiveness of LLLT in alleviating orthodontic pain observed after elastomeric separator placement (ESP) exhibited conflicting results. While LLLT was found to be effective in some studies, the others refuted its effectiveness.

The intensity of orthodontic pain was evaluated either subjectively by visual analog scale (VAS) or objectively by chemical analysis of gingival crevicular fluid (GCF), in previous studies. The analysis of GCF is a useful and non-invasive method for detecting the biochemical mediators released during tooth movement with reasonable sensitivity. In GCF, pro-inflammatory mediators such as interleukin 1-beta (IL-1β) and prostaglandin E2 (PGE2) and neuropeptides such as Substance P (SP) have been related separately to pain. When studies on alleviating orthodontic pain observed after ESP were reviewed, it was determined that the effects of many drugs and LLLT were evaluated subjectively by VAS. Furthermore, only in one study, the effects of ibuprofen and LLLT were compared using PGE2 levels in GCF and VAS. Based on that, this study was aimed to compare the effects of ibuprofen and LLLT in alleviating orthodontic pain observed after ESP through IL-1β and SP levels in GCF and VAS. The null hypothesized was that there was no difference between the effects of ibuprofen and LLLT in orthodontic pain relief.

A total of 60 subjects who referred to the Department of Orthodontics, Faculty of Dentistry at XXXX University between October 2017 and January 2019, were included in this randomized controlled clinical trial. The inclusion criteria were as follows: being older than 18 years of age, requiring ESP at the beginning of orthodontic treatment for banding of maxillary first molars, intact maxillary dentition (exception of third molars), fully erupted maxillary first molars without any treated or not treated apical lesions, tight contacts between the posterior teeth, no pregnancy and lactation, the absence of systemic and periodontal diseases and chronic or neural pains, currently not using analgesics or antibiotics that interfere the pain perception, no contradiction to the use of ibuprofen, the absence of gingival pigmentation where the laser will be applied. The exclusion criteria were: previous orthodontic treatment, falling to complete the questionnaire and to continue to the follow-up appointments.

Sample size calculation Depending on the results of previous studies the standard deviation (σ) was considered as 11 mg/dl in this study. Furthermore, for the 0.05 type I error rate the effect size, and Z values were assumed to be 5 and 1.96, respectively. Based on this information, the sample size was found to be a minimum of 18.6 (≅19) according to the equation of sample size calculation (n=Z2σ2/d2).

Randomization The subjects were randomly assigned to ibuprofen, laser, and control groups using a simple randomization technique. The investigators asked each subject to choose one of the 60 closed envelopes that were equally divided into all groups. The male to female ratio was also equal in each group. An operator outside the study performed the random allocation. Elastomeric separators (3M Unitek, Monrovia, Calif) were inserted by a single investigator (YK) at the mesial and distal interproximal spaces of the maxillary first molars.

Study groups While the ibuprofen group received 400-mg ibuprofen orally 1 hour before ESP, the laser group received a single irradiation of low-level laser immediately after ESP. Likewise, placebo lactose tablets were given orally to the control group 1 hour before ESP. The ibuprofen and placebo lactose tablets were placed in identical capsules in order to blind the subjects and investigator to the treatment group. Subjects were told not to take any other analgesic during the observation period.

Laser parameters and procedure An 810-nm semi-conductor Gallium Aluminum Arsenide (Ga-Al-As) diode laser device (Cheese Diode Laser, Wuhan Gigaa Optronics Technology Co. Ltd., China) with continuous emission mode was used for this study. For each quadrant, a total of 8 doses of laser irradiation (2 J/cm2, 100mW, 10 sn) were applied to the cervical third of the roots. The mesial and distal of the first molars, mesial of the second premolars and distal of the second molars were irradiated from both buccal and palatal sides. During the exposure, the tip held perpendicular and in contact with the mucosa.

Pain assessment Subject's pain intensity was evaluated by means of a questionnaire containing VAS (10-cm horizontal line with the number 0 representing no pain and the number 10 representing the worst pain). While baseline evaluations were made immediately after ESP in the ibuprofen and control groups, it was made after laser application in the laser group. The remaining evaluations were performed at the 2nd and 6th hours, and on the 1st, 3rd, and 7th days. Each subject was asked to mark a vertical line crossing the horizontal line, which best represented the perceived level of pain, on the questionnaire containing the evaluation time points given to them.

Gingival crevicular fluid (GCF) sampling GCF samples were collected from the mesiobuccal and distobuccal gingival crevices of maxillary first molars on day 0 (immediately after ESP in the ibuprofen and control groups and after laser application in the laser group) and on the 1st, 3rd, and 7th days. Prior to GCF sampling, the teeth were washed, gently air-dried and isolated with cotton rolls. Standardized sterile paper strips (Periopaper, Proflow, Inc., Amityville, NY) were gently inserted into the gingival crevices until mild resistance was felt and were left in place for 30 seconds. After removing the first strip and waiting for one minute, a second strip was placed on the same side for another 30 seconds. Strips contaminated with blood or exudate were discarded. Samples were then placed separately into coded, sealed plastic microcentrifuge tubes, covered with paraffin and stored at -70 oC until the day of analysis.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tuşba
      • Van, Tuşba, Turkey, 65050
        • Van Yuzuncu Yıl University, Faculty of Dentistry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Being older than 18 years of age,
  • Requiring ESP at the beginning of orthodontic treatment for banding of maxillary first molars,
  • Intact maxillary dentition (exception of third molars),
  • Fully erupted maxillary first molars without any treated or not treated apical lesions,
  • Tight contacts between the posterior teeth,
  • No pregnancy and lactation,
  • The absence of systemic and periodontal diseases and chronic or neural pains,
  • Currently not using analgesics or antibiotics that interfere the pain perception,
  • No contradiction to the use of ibuprofen,
  • The absence of gingival pigmentation where the laser will be applied.

Exclusion Criteria:

  • Previous orthodontic treatment,
  • Falling to complete the questionnaire and to continue to the follow-up appointments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: FACTORIAL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Ibuprofen group
Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
ACTIVE_COMPARATOR: Laser group
Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
A single irradiation of laser after elastomeric separator placement
PLACEBO_COMPARATOR: Control group
Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
Placebo lactose tablets 1-hour before elastomeric separator placement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation the intensity of orthodontic pain after ibuprofen administration and laser application: levels of mediators such as interleukin 1-Beta and Substance P.
Time Frame: This primary outcome was evaluated trough the study completion, on average of 1 year.
The intensity of pain observed after elastomeric separator placement was evaluated through levels of mediators such as interleukin 1-Beta and Substance P in gingival crevicular fluid objectively.
This primary outcome was evaluated trough the study completion, on average of 1 year.
Evaluation the intensity of orthodontic pain after ibuprofen administration and laser application: visual analogue scale.
Time Frame: This primary outcome was evaluated trough the study completion, on average of 1 year.
The intensity of pain observed after elastomeric separator placement was evaluated through visual analogue scale subjectively. Visual analogue scale is a 10-cm horizontal line with the number 0 representing no pain and the number 10 representing the worst pain.
This primary outcome was evaluated trough the study completion, on average of 1 year.
Comparison of the effects of ibuprofen and laser therapy in alleviating orthodontic pain observed after elastomeric separator placement: evels of mediators such as interleukin 1-Beta and Substance P.
Time Frame: This primary outcome was evaluated through the study completion, on average 1 year.
The intensity of pain observed after elastomeric separator placement was evaluated through levels of mediators such as interleukin 1-Beta and Substance P in gingival crevicular fluid objectively.
This primary outcome was evaluated through the study completion, on average 1 year.
Comparison of the effects of ibuprofen and laser therapy in alleviating orthodontic pain observed after elastomeric separator placement: visual analogue scale.
Time Frame: This primary outcome was evaluated through the study completion, on average 1 year.
The intensity of pain observed after elastomeric separator placement was evaluated through visual analogue scale subjectively.Visual analogue scale is a 10-cm horizontal line with the number 0 representing no pain and the number 10 representing the worst pain.
This primary outcome was evaluated through the study completion, on average 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 1, 2017

Primary Completion (ACTUAL)

August 1, 2018

Study Completion (ACTUAL)

August 1, 2018

Study Registration Dates

First Submitted

August 22, 2019

First Submitted That Met QC Criteria

August 26, 2019

First Posted (ACTUAL)

August 28, 2019

Study Record Updates

Last Update Posted (ACTUAL)

August 29, 2019

Last Update Submitted That Met QC Criteria

August 26, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 26.07.2017/04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crowding, Tooth

Clinical Trials on 400 Mg Ibuprofen

Search Similar Trials